Himalaya Nutravedics India Ltd vs SUN PHARMACEUTICAL IND L

A side-by-side comparison of Himalaya Nutravedics India Ltd (HNIL) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads HNIL vs SUNPHARMA on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth· not comparable—
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
37.97
0.00
P/B ratio
20.07
0.00%
Dividend yield
0.86%
₹0.00
EPS
₹47.84

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

0.00%
Return on equity
16.00%
0.00%
Return on capital
21.00%
0.00%
EBITDA margin
28.00%
0.00%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

—
Revenue CAGR (3Y) even
10.03%
—
Profit CAGR (3Y) even
10.57%

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹106 Cr
Market cap
₹4.36L Cr
₹0 Cr
Revenue
₹58,462 Cr
₹0 Cr
Net profit
₹11,509 Cr
0.00
Debt / equity
0.61
SUN PHARMACEUTICAL IND L
  • + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
  • − ["Stock is trading at 5.22 times its book value"]
Himalaya Nutravedics India Ltd full analysis SUN PHARMACEUTICAL IND L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

HNIL vs SUNPHARMA: Share Price, Valuation & Which to Buy | DocStoX